Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tilmann Bochtler

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
International Journal of Cancer|April 10, 2019
Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndromeTilmann Bochtler, Volker Endris, Jonas Leichsenring, et al.
Cancers|June 24, 2022
Cancer-of-Unknown-Primary-Origin: A SEER-Medicare Study of Patterns of Care and Outcomes among Elderly Patients in Clinical PracticeLinda Mileshkin, Tilmann Bochtler, Gemma Gatta, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 13, 2018
Integrated Histogenetic Analysis Reveals <i>BAP1</i>-Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown PrimaryTilmann Bochtler, Volker Endris, Anna Reiling, et al.
European Journal of Cancer (Oxford, England : 1990)|September 14, 2021
Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primaryMaria Pouyiourou, Timothy Wohlfromm, Bianca Kraft, et al.
Haematologica|February 22, 2008
Evaluation of the serum-free light chain test in untreated patients with AL amyloidosisTilmann Bochtler, Ute Hegenbart, Christiane Heiss, et al.
Blood|April 9, 2010
Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvementSascha Dietrich, Stefan O Schönland, Axel Benner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2015
Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimensTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Haematologica|January 19, 2019
Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmiaTobias Dittrich, Axel Benner, Christoph Kimmich, et al.
Blood|June 4, 2016
Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up studyTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 25, 2014
Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasoneTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
International Journal of Cancer|April 10, 2019
Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndromeTilmann Bochtler, Volker Endris, Jonas Leichsenring, et al.
Cancers|June 24, 2022
Cancer-of-Unknown-Primary-Origin: A SEER-Medicare Study of Patterns of Care and Outcomes among Elderly Patients in Clinical PracticeLinda Mileshkin, Tilmann Bochtler, Gemma Gatta, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 13, 2018
Integrated Histogenetic Analysis Reveals <i>BAP1</i>-Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown PrimaryTilmann Bochtler, Volker Endris, Anna Reiling, et al.
European Journal of Cancer (Oxford, England : 1990)|September 14, 2021
Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primaryMaria Pouyiourou, Timothy Wohlfromm, Bianca Kraft, et al.
Haematologica|February 22, 2008
Evaluation of the serum-free light chain test in untreated patients with AL amyloidosisTilmann Bochtler, Ute Hegenbart, Christiane Heiss, et al.
Blood|April 9, 2010
Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvementSascha Dietrich, Stefan O Schönland, Axel Benner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2015
Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimensTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Haematologica|January 19, 2019
Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmiaTobias Dittrich, Axel Benner, Christoph Kimmich, et al.
Blood|June 4, 2016
Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up studyTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 25, 2014
Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasoneTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Pageof 6